Novo Nordisk Pays $1.80bn To Buy Emisphere
Acquires Technology Used For Diabetes Pill Rybelsus
Executive Summary
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
You may also be interested in...
Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports